GL Pharm Tech Corp.
Research GL Pharm Tech Corp. (204840.KQ) on Bullrun: market cap KRW 61.03B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker204840.KQ
- ExchangeKQ
- CountrySouth Korea
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
- CurrencyKRW
- Market capKRW 61.03B
- Financial periodQ2 2026
- RevenueKRW 9.70B
- Net incomeKRW 81.53M
- Free cash flowKRW 204.84M
- Gross margin43.8%
Valuation Snapshot
latest market cap is KRW 61.03B.
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-18 | KRW 61.03B | n/a | n/a | n/a |
Dividend history
About GL Pharm Tech Corp.
GL Pharm Tech Corp. provides generic drugs and incrementally modified drug (IMD) formulation technology to pharmaceutical companies in South Korea. The company offers IMD for gastritis, antidepressant, anorectic, and antibiotic indications. It also provides generic drugs for cardiovascular, urology, pain, anti-infection, gastric disease, diabetes, central nervous system disease, respiratory disease, transplantation, and other areas.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is GL Pharm Tech Corp.'s market cap?
GL Pharm Tech Corp.'s market capitalization is KRW 61.03B.
What does GL Pharm Tech Corp. do?
GL Pharm Tech Corp. provides generic drugs and incrementally modified drug (IMD) formulation technology to pharmaceutical companies in South Korea. The company offers IMD for gastritis, antidepressant, anorectic, and antibiotic indications. It also provides generic drugs for cardiovascular, urology, pain, anti-infection, gastric disease, diabetes, central nervous system disease, respiratory disease, transplantation, and other areas. In addition, the company engages in developing new molecule entity pipeline products for dry eye disease.